A source in the Russian Direct Investment Fund said that he is negotiating with some pharmaceutical companies to increase production of “Sputnik V” in the European Union countries.
The source stated that the fund is ready to start deliveries of the vaccine to European Union countries, which register the vaccine independently.
The source added, “Since the beginning of the fight against the epidemic, the fund has tended to actively cooperate with all partners, including from Europe, and it is open to negotiations on this. The fund has reached agreements with companies from Italy, Spain, France and Germany, to launch the production of Sputnik V. In” At the moment, we are in negotiations with a number of manufacturers to increase vaccine production in the European Union. “
According to him, this will allow the start of active deliveries of “Sputnik V” vaccines, to the European single market after obtaining the approval of the European Medicines Agency, with which there is currently active cooperation in the framework of considering the submitted application (rolling review).